^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ERVE-4 (Endogenous Retrovirus Group E Member 4)

    i
    Other names: ERVE-4, Endogenous Retrovirus Group E Member 4, CT-RCC HERV-E , Endogenous Retrovirus Group E, Member 4
    12ms
    HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. (PubMed, Cell)
    Moreover, ERV expression can be induced in non-ccRCC tumors with clinical-grade HIF stabilizers. These findings have implications for leveraging ERVs for cancer immunotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • ERVE-4 (Endogenous Retrovirus Group E Member 4)
    |
    TMB-L
    almost2years
    Human endogenous retroviruses (HERVs) in breast cancer: altered expression pattern implicates divergent roles in carcinogenesis. (PubMed, Oncology)
    Conclusion Differential HERVs expression may be applicable to evaluate novel biomarkers for breast cancer. However, more research is needed to reveal their real clinical impact, the biological roles and regulatory mechanisms in breast carcinogenesis.
    Journal
    |
    ERVE-4 (Endogenous Retrovirus Group E Member 4)
    over2years
    Derepression of Human Endogenous Retrovirus and Implications for Immunotherapy for Clear CellRenal Cell Carcinoma (KCRS 2023)
    In addition, hERV-derived peptides that arepresented on MHCs and recognizable by T cells could form the basis for future T-cell therapies and cancer vaccine, a step towardpersonalized medicine for kidney cancer patients. The knowledge gained from HIF regulated hERV could guide me to establish a careerbridging basic biology of kidney cancer to novel therapy development.
    Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • ERVE-4 (Endogenous Retrovirus Group E Member 4) • TINCR (TINCR Ubiquitin Domain Containing)
    |
    TMB-L • VHL mutation